Comparing the current results to its competitors, Atara Biotherapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -96.44 %, despite the revenue increase by the most of its competitors of 12.63 %, recorded in the same quarter.
Atara Biotherapeutics Inc 's Comment on Competition and Industry Peers
The biotechnology and pharmaceutical industries are characterized by intense competition and rapid technological advancements, with a focus on proprietary products. The company competes with numerous pharmaceutical and biotechnology firms, as well as academic institutions, government agencies, and both private and public research organizations. Some competitors possess greater market presence, financial resources, technologies, scientific tools, and expertise. The company's commercial opportunities could be diminished or eliminated if competitors develop products that are safer, more effective, more convenient, or less expensive. There are ongoing commercial and academic clinical studies in immunotherapy, particularly in T-cell immunotherapy. Currently, no FDA-approved products exist for relapsed and/or refractory EBV+ PTLD, and the only EC-approved product is Ebvallo. The company's patents may be subject to challenges or circumvention, and competitors may develop similar drugs or duplicate technologies without infringing on patents. Additionally, the lengthy clinical development and regulatory review process may reduce the effective patent protection period following commercialization.
January 16, 2025
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a prominent player in the field of T-cell immunotherapy, has recently been in the spotlight following significant developments regarding its lead therapeutic candidate, EBVALLO™ (tabelecleucel). This allogeneic Epstein-Barr virus (EBV) T-cell therapy aims to provide transformative solutions for patients suffering from cancer and autoimmune diseases. However, the journey towards regulatory approval has encountered obstacles, underscored by a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). Regulatory Setback The Complete Response LetterThe FDA s CRL indicates that the agency has not approved Atara s Biologics License Application ...
August 13, 2024
Transformative Strides in T-Cell Therapeutics: Atara Biotherapeutics Announces Financial Results and Operational Progress for Q2 2024 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a trailblazer in T-cell immunotherapy, has announced its financial results for the second quarter of 2024 alongside critical operational advancements and leadership updates. This synopsis captures the notable achievements and forward-looking milestones of this pioneering biotech firm. Utilizing its pioneering allogeneic Epstein-Barr virus (EBV) T-cell platform, Atara aims to develop revolutionary therapies targeting malignancies and autoimmune disorders. Atara Biotherapeutics’ sustained focus on allogeneic T-cell immunotherapy has...
July 17, 2024
Atara Biotherapeutics, a frontrunner in T-cell immunotherapy, is making significant strides in the development of revolutionary therapies for patients battling cancer and autoimmune diseases. The recent acceptance and priority review of their Biologics License Application (BLA) for Tabelecleucel (Tab-cel) by the U.S. Food and Drug Administration (FDA) marks a milestone achievement for the company. Simultaneously, Atara Biotherapeutics presented encouraging preclinical data for ATA3219, an allogeneic CD19-targeted CAR T-cell therapy for B-cell driven autoimmune diseases. This article delves into the details of these groundbreaking developments and their potential impact on the medical landscape.The Promise of...
May 20, 2024
By Author Name Published in CSIMarket.com Thousand Oaks, Calif. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, has recently announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for their critical product, tabelecleucel (tab-cel). This significant milestone may pave the way for a promising therapeutic avenue to treat Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD), particularly targeting both adult and pediatric patients. Groundbreaking Therapy: Tabelecleucel (Tab-cel) Tabelecleucel is an alloegeneic T-cell therapy sourced from Atara’s innovative Epstein-Barr virus T-cell platf...
Publicly Traded Peers of Atara Biotherapeutics Inc
Vincerx Pharma Inc Share Performance
0.00%
Over The Past 5 Days
Vincerx Pharma Inc
Profile
Vincerx Pharma Inc's business model is focused on developing and commercializing novel small molecule drugs for the treatment of cancer. They aim to leverage their scientific expertise and collaborations to identify and advance promising drug candidates, ultimately providing innovative therapies to patients in need.
Elevai Labs Inc operates on a subscription-based model, providing users with access to their proprietary software platform that utilizes artificial intelligence technology. The platform is designed to assist businesses in automating mundane and repetitive tasks, improving operational efficiency. Elevai Labs generates revenue through monthly or annual fees charged to their customers based on the level of usage.
Cabaletta Bio Inc's business model revolves around developing and commercializing genetically engineered T cell therapies for the treatment of autoimmune diseases. They aim to utilize their proprietary technology platform to engineer Chimeric AutoAntibody Receptor (CAAR) T cells, which are designed to selectively target and eliminate disease-causing B cells. By focusing on autoimmune diseases with high unmet medical needs, Cabaletta Bio Inc aims to provide effective and personalized therapeutic solutions to patients.
Sources:
Atara Biotherapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Atara Biotherapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
